SecBot SecBot
SECBOTREPLAY Home › Report › ATRA

ATRA · Atara Biotherapeutics announced that a Type A meeting with the FDA has…

Atara Biotherapeutics, Inc. · 8-K filed Mar 12, 2026 at 08:11 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Mar 12, 2026 at 08:11 ET

Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the Complete Response Letter for the Biologics License Application of tabelecleucel (tab-cel), developed with partner Pierre Fabre Pharmaceuticals. The company expects to provide a regulatory update in the second quarter of 2026.

  • Atara Biotherapeutics announced a scheduled Type A meeting with the FDA on March 12, 2026.
  • The meeting will address the Complete Response Letter (CRL) for the Biologics License Application (BLA) of tabelecleucel (tab-cel).
  • The BLA is held by partner Pierre Fabre Pharmaceuticals, with Atara's support.
  • The purpose is to discuss resubmission with additional efficacy data collected since the original submission.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access